Aqueous suspension for nasal administration of loteprednol

摘要

Loteprednol etabonate having excellent anti-inflammatory and antiallergenic activities is expected to be developed as a drug for external application but when it is formulated into an aqueous suspension, the aggregation and precipitation of particles tend to take place. According to the present invention, long-term stabilisation of the suspension was successfully achieved by formulating loteprednol etabonate with microcrystalline cellulose carmellose sodium. Moreover, the resulting suspension features a remarkably improved intranasal retention and no dermal or mucosal irritation.